RET and cancer: In addition, ESMO recommendations for actionable genomic alterations in advanced TC, including RET alteration-driven cancer and cancers with NTRK fusions, and next-generation sequencing (NGS), are in place to support guidelines for TC testing and treatment (41, 42, 43), but do not define the ideal timing for TC testing.